A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea
Latest Information Update: 07 Nov 2021
At a glance
- Drugs IONIS-PTP1BRx (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
- 09 Feb 2018 Primary endpoint(Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy) has not been met,according to Results published in the Diabetes Care
- 09 Feb 2018 Results published in the Diabetes Care
- 02 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.